Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diphenoxylate→

Diphenoxylate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
915-30-0
Molecular formula
C30H32N2O2
Molecular weight
452.6 g/mol
Drug class
Peripheral opioid antidiarrhoealmu-opioid receptor agonist
Mechanism of action
Activates opioid receptors in the intestinal wall, reducing propulsive peristalsis and prolonging intestinal transit time, which increases fluid and electrolyte absorption. It is commonly combined with atropine to discourage misuse.
Indications / reported uses
  • Adjunctive treatment of acute nonspecific diarrhoea in adults and children aged 13 years and older under the US product label, with fluid and electrolyte replacement as needed; not for bloody diarrhoea, invasive enteritis or toxin-mediated diarrhoea without evaluation

Sources: US DailyMed — Diphenoxylate/atropine · NLM MeSH — Diphenoxylate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Diphenoxylate Environmental Risk Assessment (ERA) (the Diphenoxylate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.